Kalvista Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Kalvista Pharmaceuticals
KALV Stock  USD 15.61  0.04  0.26%   
Kalvista Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kalvista Pharmaceuticals' valuation are provided below:
Gross Profit
-59.4 M
Market Capitalization
782 M
Enterprise Value Revenue
442.8306
Revenue
1.4 M
Earnings Share
(3.94)
There are over one hundred nineteen available fundamental ratios for Kalvista Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should should check Kalvista Pharmaceuticals' last-minute fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable. Enterprise Value is likely to climb to about 183.8 M in 2026, whereas Market Cap is likely to drop slightly above 86.5 M in 2026.

Kalvista Pharmaceuticals Total Revenue

27,550

Check Kalvista Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kalvista Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 0.0 or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 46.95, Dividend Yield of 0.0 or Days Sales Outstanding of 273. Kalvista financial statements analysis is a perfect complement when working with Kalvista Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Kalvista Stock
Check out the analysis of Kalvista Pharmaceuticals Correlation against competitors.
For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

Kalvista Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets111 M56.8 M101.1 M
Slightly volatile
Short and Long Term Debt Total5 M4.6 M4.1 M
Slightly volatile
Other Current Liabilities27.6 K29 K4.9 M
Slightly volatile
Total Current Liabilities4.1 M4.3 M11.1 M
Slightly volatile
Property Plant And Equipment Net4.1 M2.3 M3.2 M
Slightly volatile
Current Deferred Revenue13.3 M12.7 M8.2 M
Slightly volatile
Accounts Payable2.8 M1.5 M2.3 M
Slightly volatile
Cash37.6 M53.7 M34.2 M
Slightly volatile
Non Current Assets Total11 M10.4 M4.7 M
Slightly volatile
Non Currrent Assets Other922.3 K1 M831.8 K
Slightly volatile
Cash And Short Term Investments96.4 M53.7 M85.6 M
Slightly volatile
Common Stock Total Equity18.1 K31.1 K16.4 K
Slightly volatile
Common Stock Shares Outstanding60 M57.1 M19.6 M
Slightly volatile
Liabilities And Stockholders Equity302.8 M288.4 M124.1 M
Slightly volatile
Non Current Liabilities Total133.1 M126.7 M35.2 M
Slightly volatile
Other Current Assets959.5 K1 M4.4 M
Slightly volatile
Total Liabilities7.1 M7.5 M29.1 M
Very volatile
Property Plant And Equipment Gross764.8 K805 K3.8 M
Slightly volatile
Total Current Assets106.7 M54.9 M97.1 M
Slightly volatile
Short Term Debt1.2 M1.5 M1.6 M
Slightly volatile
Common Stock20.2 K27 K18.5 K
Slightly volatile
Long Term Debt Total1.4 M2.8 M1.9 M
Slightly volatile
Capital Surpluse255 M140.2 M181.4 M
Slightly volatile
Property Plant Equipment1.3 M925.8 K1.1 M
Slightly volatile
Net Receivables2.1 M2.2 M6.9 M
Slightly volatile
Short and Long Term Debt1.1 M1.8 M1.7 M
Very volatile
Net Invested Capital139.9 M109.7 M93.1 M
Slightly volatile
Net Working Capital151.4 M226 M106.1 M
Slightly volatile
Other Liabilities5.7 M3 M7 M
Slightly volatile
Capital Lease Obligations5.2 M7.3 M3 M
Slightly volatile
Capital Stock33 K57.5 K25.7 K
Slightly volatile
Non Current Liabilities Other5.2 M8.2 M4.6 M
Slightly volatile

Kalvista Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.1 M1.1 M424.5 K
Slightly volatile
Selling General Administrative4.6 M4.9 M18.3 M
Slightly volatile
Other Operating Expenses227 M216.2 M72.4 M
Slightly volatile
Research Development15.4 M16.2 M30.7 M
Slightly volatile
Total Operating Expenses20 M21.1 M39.1 M
Slightly volatile
Interest Income2.1 M1.2 M1.3 M
Slightly volatile
Non Recurring1.2 M1.3 M1.4 M
Slightly volatile
Net Interest Income1.5 M747.5 K856.5 K
Slightly volatile
Reconciled Depreciation572.7 K1.1 M387.1 K
Slightly volatile
Selling And Marketing Expenses652.8 K734.4 K801.6 K
Slightly volatile

Kalvista Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation14.8 M14.1 M5.9 M
Slightly volatile
Begin Period Cash Flow3.7 M3.9 M21.4 M
Slightly volatile
Depreciation126.3 K133 K320.7 K
Slightly volatile
Capital Expenditures490.5 K659 K479.2 K
Slightly volatile
Total Cash From Financing Activities56.5 M72.1 M54.1 M
Slightly volatile
End Period Cash Flow9.3 M9.8 M30.3 M
Slightly volatile
Sale Purchase Of Stock41.2 M78.3 M41.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio46.9558.0743.8127
Very volatile
Days Sales Outstanding273428299
Slightly volatile
Stock Based Compensation To Revenue0.01710.0180.1087
Slightly volatile
Capex To Depreciation2.013.28951.7525
Very volatile
EV To Sales39.2459.7739.6489
Pretty Stable
Payables Turnover0.00690.00734.3137
Slightly volatile
Sales General And Administrative To Revenue0.971.031.504
Pretty Stable
Research And Ddevelopement To Revenue5.355.285.0708
Pretty Stable
Capex To Revenue0.04810.06240.0558
Slightly volatile
Cash Per Share3.163.32985.9818
Pretty Stable
Days Payables Outstanding54.5 K51.9 K24.3 K
Very volatile
Current Ratio0.610.64677.7752
Pretty Stable
Receivables Turnover0.840.882.6777
Slightly volatile
Capex Per Share0.110.10680.0481
Pretty Stable
Revenue Per Share1.021.771.1075
Slightly volatile
Interest Debt Per Share5.895.61031.7873
Very volatile
Debt To Assets1.040.98830.2579
Pretty Stable
Days Of Payables Outstanding54.5 K51.9 K24.3 K
Very volatile
Ebt Per Ebit0.960.89330.8653
Very volatile
Quick Ratio0.610.64677.7752
Pretty Stable
Net Income Per E B T1.091.171.0051
Pretty Stable
Cash Ratio0.520.54943.4294
Slightly volatile
Days Of Sales Outstanding273428299
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.01961.008
Pretty Stable
Fixed Asset Turnover12.7811.5313.2348
Slightly volatile
Debt Ratio1.040.98830.2579
Pretty Stable
Price Sales Ratio46.9558.0743.8127
Very volatile
Asset Turnover0.330.310.1884
Slightly volatile

Kalvista Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap86.5 M91.1 M188.7 M
Slightly volatile
Enterprise Value183.8 M93.8 M169.5 M
Slightly volatile

Kalvista Fundamental Market Drivers

Forward Price Earnings19.084
Cash And Short Term Investments187.6 M

Kalvista Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
5th of July 2024
Next Financial Report
View
31st of January 2024
Next Fiscal Quarter End
View
5th of July 2024
Next Fiscal Year End
View
31st of October 2023
Last Quarter Report
View
30th of April 2023
Last Financial Announcement
View

About Kalvista Pharmaceuticals Financial Statements

Kalvista Pharmaceuticals investors use historical fundamental indicators, such as Kalvista Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kalvista Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue12.7 M13.3 M
Total Revenue29 K27.6 K
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 1.03  0.97 
Research And Ddevelopement To Revenue 5.28  5.35 
Capex To Revenue 0.06  0.05 
Revenue Per Share 1.77  1.02 
Ebit Per Revenue(4.04)(4.24)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY